hPSCreg as a resource in IRDiRC

Posted on January 15, 2020

We are pleased that hPSCreg is now entered as a recognized resource in the International Rare Diseases Research Consortium ( IRDiRC ).

Patient-derived hiPSC lines are valuable source reagents for producing specific cell types for use in individualized disease modeling and drug testing, especially for rare diseases. As an established human pluripotent stem cell line registry, hPSCreg is well-positioned to serve as the central registry for hiPSC lines from rare disease patients. We would like to increase the findability of rare patient cell lines, to encourage the usage of existing lines and avoid duplication of work, and to promote sharing of resources.